A doctor sits with Tram Mai to discuss what we should know about GLP-1 drugs and their side effects. McDonald's CEO prepares ...

The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular ...

A new survey suggests about three million Canadian adults are currently taking GLP-1 drugs such as Ozempic or Mounjaro and ...

GLP-1 drugs Ozempic, Wegovy, Mounjaro and Zepbound can help patients lose anywhere from 15% to 20% of body weight. But what ...

Consumer health advertising is driving many employees to take action on GLP-1s. But without guidance, those decisions could be risky.

GLP-1 receptor agonists hold key market opportunities due to their effectiveness in diabetes and obesity management, expanding to cardiovascular and neurodegenerative disorders. Innovations like oral ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...

People on GLP-1s had slightly higher risks of osteoporosis and gout than similar people not taking these drugs. But diet and ...

In a recent review, a small group of patients received the injections less frequently but still maintained weight loss and health benefits.

Obesity dipped in Minnesota as GLP‑1 use rose. Experts warn the long‑term picture and who pays are still unsettled.

Popular GLP-1 receptor agonist drugs for weight loss, also known as GLP-1 RAs, appear to be similarly effective among ...